荆花胃康胶丸联合双歧杆菌三联活菌治疗低载量幽门螺杆菌感染脾胃湿热证临床研究被引量：1

Retrospective study on Jinghua Weikang capsule combined with Bifidobacterium in the treatment of spleen-somach damp-heat syndrome featured by helicobacter pylori infection with low count

原文传递

导出

摘要目的评价荆花胃康胶丸联合双歧杆菌三联活菌治疗低载量Hp感染脾胃湿热证的疗效。方法选取2019年3月-2020年3月首都医科大学附属北京中医医院消化中心门诊患者130例,按治疗方案分为四联组与二联组,每组65例。四联组给予2种不同的治疗方案,其中34例采用方案1(雷贝拉唑钠肠溶片+枸橼酸铋钾胶囊+阿莫西林胶囊+克拉霉素),31例采用方案2(雷贝拉唑钠肠溶片+枸橼酸铋钾胶囊+阿莫西林胶囊+左氧氟沙星片);二联组给予荆花胃康胶丸+双歧杆菌三联活菌胶囊治疗。四联组14 d为1个疗程,二联组28 d为1个疗程,2组均治疗1个疗程。分别于治疗前后进行中医证候评分,停药后4周采用13C-UBT法检测Hp,观察Hp根除率,记录治疗期间的不良反应,评价临床疗效。结果四联组Hp根除率为90.8%(59/65)、二联组为78.5%(51/65),2组Hp根除率比较,差异无统计学意义(χ^(2)=3.78,P=0.052)。四联组方案1的Hp根除率为91.2%(31/34)、方案2为90.3%(28/31),2种方案的Hp根除率比较,差异无统计学意义(χ^(2)=0.01,P=0.906)。四联组治疗后中医证侯评分[(7.02±0.89)分比(6.51±0.85)分;Z=-3.01,P<0.01]高于二联组。二联组总有效率为93.8%(61/65)、四联组为78.5%(51/65),2组比较差异有统计学意义(χ^(2)=6.45,P=0.011)。四联组不良反应发生率为24.6%(16/65)、二联组为6.2%(4/65),2组比较差异有统计学意义(χ^(2)=8.51,P=0.004)。结论荆花胃康胶丸联合双歧杆菌三联活菌方案对低载量Hp感染患者具有一定的抗Hp作用,可改善患者中医症状,减少不良反应。 Objective To investigate the clinical efficacy of Jinghua Weikang capsule combined with Bifidobacterium for curing patients featured by spleen-stomach damp-heat syndrome and Helicobacter pylori(Hp)infection with low DOB values.Methods To enroll 130 cases who were admitted to the Digestion Center of Beijing Hospital of Traditional Chinese Medicine,Capital Medical University from March 2019 to March 2020.According to the treaatment protocols,the quadruple therapy group and dual therapy group,each had 65 patients.The quadruple therapy group had two different treatment protocols,34 cases with Rabeprazole sodium enteric-coated tablet,Bismuth potassium citrate capsule,Amoxicillin capsule,and Clarithromycin,the other one had 31 cases with Rabeprazole sodium enteric-coated tablet,Bismuth potassium citrate capsule,Amoxicillin capsule,and Levofloxacin tablets.The Dual therapy group was treated with Jinghua Weikang capsule combined with Bifidobacterium.As for quadruple therapy group,14 days was a course of treatment,while28 days was a course of treatment for dual therapy group.The two groups were treated for one course,respectively.The TCM syndromes were scored before and after treatment.After 4-weeks long drug withdrawal,all cases were reexamined via 13C-UBT.The Hp eradication rate,efficacy evaluation and adverse reactions were compared between both groups.Results The eradication rate was 90.8%(59/65)in quadruple therapy group and 78.5%(51/65)in dual therapy group.There was no statistical difference between two groups(χ^(2)=3.78,P=0.052).As for quadruple therapy group,the eradication rate was 91.2%(31/34)in Protocol One and 90.3%(28/31)in Protocol Two.There was no statistical difference between two protocols(χ^(2)=0.01,P=0.906).After treatment,the TCM syndrome score of quadruple therapy group[(7.02±0.89)vs.(6.51±0.85),Z=-3.01],was significantly higher than that of dual therapy group(P<0.01).The total effective rate was 93.9%(61/65)in dual therapy group and 78.5%(51/65)in quadruple therapy group.There was statistically

作者王秋明胡晶丁洋刘继红张声生 Wang Qiuming;Hu Jing;Ding Yang;Liu Jihong;Zhang Shengsheng(The Digestion Center,Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University,Beijing 100010,China;Centre for Evidence-Based Medicine,Beijing Institute of Traditional Chinese Medicine,Beijing 100010,China)

机构地区首都医科大学附属北京中医医院消化中心北京市中医研究所循证医学中心

出处《国际中医中药杂志》 2022年第7期734-738,共5页 International Journal of Traditional Chinese Medicine

基金北京市医院管理局重点医学专业发展计划项目(ZYLX201411)。

关键词幽门螺杆菌低载量幽门螺杆菌感染荆花胃康胶丸双歧杆菌三联活菌根除率不良反应 Helicobacter pylori Hp infection with low delta over baseline values Jinghua Weikang capsule Bifidobacterium Eradication rates Adverse reactions

分类号 R573 [医药卫生—消化系统]